850832-54-1 Usage
General Description
Methyl 4-bromo-5-methyl-3-isoxazolecarboxylate is a chemical compound with a molecular formula C7H8BrNO3. It is a colorless to pale yellow liquid with a melting point of 35-37°C and a boiling point of 155-157°C. methyl 4-bromo-5-methyl-3-isoxazolecarboxylate(SALTDATA: FREE) is commonly used in the synthesis of pharmaceuticals and agrochemicals. It is also known for its high reactivity and is used as an intermediate in organic synthesis. Additionally, it is known to have potential applications in the fields of medicine, biology, and materials science. This chemical is available as a free base and is commonly utilized in research and industrial processes.
Check Digit Verification of cas no
The CAS Registry Mumber 850832-54-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,0,8,3 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 850832-54:
(8*8)+(7*5)+(6*0)+(5*8)+(4*3)+(3*2)+(2*5)+(1*4)=171
171 % 10 = 1
So 850832-54-1 is a valid CAS Registry Number.
850832-54-1Relevant articles and documents
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo
Vickers, Clare F.,Silva, Ana P. G.,Chakraborty, Ajanta,Fernandez, Paulina,Kurepina, Natalia,Saville, Charis,Naranjo, Yandi,Pons, Miquel,Schnettger, Laura S.,Gutierrez, Maximiliano G.,Park, Steven,Kreiswith, Barry N.,Perlin, David S.,Thomas, Eric J.,Cavet, Jennifer S.,Tabernero, Lydia
, p. 8337 - 8352 (2018/09/18)
Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host. We report here the structure-based design of selective MptpB inhibitors that reduce survival of multidrug-resistant tuberculosis strains in macrophages and enhance killing efficacy by first-line antibiotics. Monotherapy with an orally bioavailable MptpB inhibitor reduces infection burden in acute and chronic guinea pig models and improves the overall pathology. Our findings provide a new paradigm for tuberculosis treatment.
